ClinicalTrials.gg
CompletedNCT00240318Updated Nov 19, 2010

A Study To Evaluate the Effect of Rosuvastatin On Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID)

A Phase 3 interventional study of Rosuvastatin calcium in Coronary Arteriosclerosis, sponsored by AstraZeneca. Completed at 61 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-11-19.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
450
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 34 studies testing rosuvastatin in Coronary Artery Disease — 2 open to participants now, 5 under way, 1 of them phase 3. rosuvastatin · Coronary Artery Disease.

Enrollment
6th of 34
450 · median 175
Started
2002
the only one that year
Phase 3
7 of 34
1 open now
Registered
1st of 34
by date
Lead sponsor
4 of 34
AstraZeneca

Among the 34 studies testing rosuvastatin in Coronary Artery Disease, this one is the 6th largest by enrollment, is the only one that started in 2002, is one of 7 in phase 3, and was the 1st registered.

Coronary Artery Disease

4,864 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

2 of the 34 studies testing rosuvastatin in Coronary Artery Disease are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About rosuvastatin

rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 589 Coronary Artery Disease studies recruiting now, 403 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing rosuvastatin in Coronary Artery Disease, or all of them as a file.
02

Study summary

The purpose of this study is to see if 40 mg of rosuvastatin taken daily will reduce the atherosclerosis (fatty deposits) in your arteries

03

Conditions studied

  • Coronary Arteriosclerosis

Keywords

  • Coronary Artery Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical indication for coronary catheterization. Target Coronary Artery: The target vessel must have .50% reduction in lumen diameter by angiographic visual estimation throughout a segment of at least 40 mm in length (the target segment) and the vessel must be large enough to accommodate the IVUS catheter. A lesion of up to 60% is permitted distal to the target segment. Side branches of the target (imaged) vessel may be narrowed up to 70% by visual estimation, provided the target segment contains no lesion greater than 50%.

Exclusion criteria

Exclusion Criteria:

Use of lipid-lowering medication for more than 3 months within the previous 12 months. Longer periods of treatment are not permitted because of the potential effects of such therapy on coronary atherosclerosis. Subjects receiving treatment with a lipid-lowering medication within the past 4 weeks require a 4-week following which a baseline lipid profile will be taken at visit 2.

heart disease which, in the opinion of the Principal Investigator (or designee), is likely to require coronary bypass surgery, cardiac transplantation, surgical repair and/or replacement during the course of the study.

-

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
450 participants

Interventions

06

What researchers measure

Primary outcomes

  1. to evaluate whether 2 years of treatment with 40 mg rosuvastatin results in regression of coronary artery atheroma burden via the total atheroma volume in the most diseased segment or the percent atheroma volume, as measured by IVUS

Secondary outcomes

  1. to evaluate whether treatment with rosuvastatin results in:

  2. Regression of coronary artery atheroma burden, as assessed by TAV

  3. Regression of coronary artery disease as measured by quantitative coronary angiography (QCA).

  4. To evaluate the change in lipid and lipoprotein levels as assessed by percentage change from baseline.

  5. To evaluate the safety of rosuvastatin

07

Study locations

61 sites
  • Research Site
    Birmingham, Alabama, United States
  • Research Site
    Los Angeles, California, United States
  • Research Site
    San Francisco, California, United States
  • Research Site
    Santa Rosa, California, United States
  • Research Site
    Stockton, California, United States
  • Research Site
    Denver, Colorado, United States
  • Research Site
    Hartford, Connecticut, United States
  • Research Site
    Atlantis, Florida, United States
  • Research Site
    Chicago, Illinois, United States
  • Research Site
    Maywood, Illinois, United States
  • Research Site
    Auburn, Maine, United States
  • Research Site
    Baltimore, Maryland, United States
  • Research Site
    Ann Arbor, Michigan, United States
  • Research Site
    Petoskey, Michigan, United States
  • Research Site
    Minneapolis, Minnesota, United States
  • Research Site
    St. Paul, Minnesota, United States
  • Research Site
    Buffalo, New York, United States
  • Research Site
    Valhalla, New York, United States
  • Research Site
    Williamsville, New York, United States
  • Research Site
    Chapel Hill, North Carolina, United States
  • Research Site
    Toledo, Ohio, United States
  • Research Site
    Danville, Pennsylvania, United States
  • Research Site
    Houston, Texas, United States
  • Research Site
    Milwaukee, Wisconsin, United States
  • Research Site
    Auchenflower, Australia
  • Research Site
    Clayton, Australia
  • Research Site
    Heidelberg, Australia
  • Research Site
    New Lambton, Australia
  • Research Site
    Aalst, Belgium
  • Research Site
    Bruxelles, Belgium
  • Research Site
    Edegem, Belgium
  • Research Site
    Liege, Belgium
  • Research Site
    Halifax, Nova Scotia, Canada
  • Research Site
    Montreal, Quebec, Canada
  • Research Site
    Ste-Foy, Quebec, Canada
  • Research Site
    Creteil, France
  • Research Site
    Limoges, France
  • Research Site
    Lyon, France
  • Research Site
    Massy, France
  • Research Site
    Melun, France
  • Research Site
    Paris, France
  • Research Site
    Pessac, France
  • Research Site
    Toulouse, France
  • Research Site
    Rozzano, Milan, Italy
  • Research Site
    Mirano, Venezia, Italy
  • Research Site
    Genova, Italy
  • Research Site
    Milan, Italy
  • Research Site
    Pavia, Italy
  • Research Site
    Pisa, Italy
  • Research Site
    Rome, Italy
  • Research Site
    Siena, Italy
  • Research Site
    Udine, Italy
  • Research Site
    Amsterdam, Netherlands
  • Research Site
    Maastricht, Netherlands
  • Research Site
    Nieuwegein, Netherlands
  • Research Site
    Zwolle, Netherlands
  • Research Site
    Barcelona, Spain
  • Research Site
    Madrid, Spain
  • Research Site
    Malaga, Spain
  • Research Site
    Murias, Spain
  • Research Site
    Valladolid, Spain
08

References and documents

Publications

  • Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM; ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006 Apr 5;295(13):1556-65. doi: 10.1001/jama.295.13.jpc60002. Epub 2006 Mar 13. PubMed 16533939 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2002, a primary completion of Nov 2005 and a completion of Nov 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2005
First posted
Oct 18, 2005
Start
Nov 2002
Primary completionActual
Nov 2005
CompletionActual
Nov 2005
Last update
Nov 19, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00240318
Lead sponsor
AstraZeneca
First posted
Oct 18, 2005
Start date
Nov 2002
Primary completion
Nov 2005
Completion
Nov 2005
Last update
Nov 19, 2010

Study contacts

AstraZeneca Crestor Medical Sciences Director, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rosuvastatin

Start the discussion